PORTLAND, Conn. (PRWEB) July 18, 2019
Michael Fedele, former Lt. Governor of Connecticut from 2007 to 2011, today announced that he will serve as a member of the Board of Directors of CTPharma, a Connecticut-based leader in the medical marijuana industry. Medical marijuana is used by patients registered with the State of Connecticut to address symptoms of cancer, AIDS, multiple sclerosis, glaucoma, epilepsy, and other medical conditions.
“I am proud to help advance the mission of a company and an industry that is helping people,” former Lt. Governor Fedele said. “It is important for policy makers and other officials to recognize the continuing scientific advancement of the legal cannabis industry because we have only scratched the surface in terms of the potential for medical treatments, pain relief and relief from the symptoms of many diseases.”
“I also believe we need to develop the regulation of medical cannabis nationally because it has the potential to help so many more people facing debilitating medical conditions than are being helped right now,” Fedele said. “I look forward to assisting CTPharma’s efforts to educate lawmakers and other national, state and local officials whose policies and actions could assure a supply of safe and effective medical cannabis to patients across America.”
In addition to serving as a Board Director, Fedele will also chair CTPharma’s Regulatory Advancement and Government Relations Committee.
Michael Fedele is the founder and CEO of Stamford-based Pinnacle Group, a nationwide IT firm. Fedele began his public service as a member of Stamford's Board of Representatives from 1987–1991. Fedele was then elected to represent Stamford's 147th District in the Connecticut House of Representatives from 1992 until 2002. On January 3, 2007, Michael Fedele was sworn in as Connecticut's 107th Lieutenant Governor.
“We are pleased to have a well-respected business-person and former State official as a member of the CTPharma board,” said Tom Schultz, CEO of CTPharma. “Mike will play a key role in our governmental relations efforts as we support Connecticut's developing legal cannabis program.”
CTPharma products are manufactured using the methods of FDA regulated industries in order to assure conformity with American expectations with respect to the company’s products.
The company’s mission is to invest in people, practices and infrastructure to shape a new industry. CTPharma ‘s goal is to be a trusted brand and to offer premium products that patients can rely on.